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Abstract
Background: Past measles immunisation policies in Australia have resulted in a cohort of young
adults who have been inadequately vaccinated, but who also have low levels of naturally acquired
immunity because immunisation programs have decreased the circulation of wild virus. A measles-
mumps-rubella (MMR) immunisation campaign aimed at addressing this susceptibility to measles
among young adults was conducted in Australia in 2001–2. By estimating age-specific immunity, we
aimed to evaluate the success of this campaign in the state of Victoria.
Methods: We conducted serosurveys after the young adult MMR program at state and national
levels to estimate immunity among young adults born between 1968–82. We compared results of
the Victorian (state) surveys with the Victorian component of the national surveys and compared
both surveys with surveys conducted before the campaign. We also reviewed all laboratory
confirmed measles cases in Victoria between 2000–4.
Results: The Victorian state serosurveys indicated no significant change in immunity of the cohort
following the young adult MMR campaign (83.9% immune pre and 85.5% immune post campaign)
while the Victorian component of the national serosurvey indicated a significant decline in immunity
(91.0% to 84.2%; p = 0.006). Both surveys indicated about 15% susceptibility to measles among
young Victorian adults after the campaign. Measles outbreaks in Victoria between 2000–4
confirmed the susceptibility of young adults. Outbreaks involved a median of 2.5 cases with a
median age of 24.5 years.
Conclusion: In Victoria, the young adult MMR program appears to have had no effect on residual
susceptibility to measles among the 1968–82 birth cohort. Young adults in Victoria, as in other
countries where past immunisation policies have left a residual susceptible cohort, represent a
potential problem for the maintenance of measles elimination.
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Reflecting previous disease circulation and vaccination
policies, it was recognised that, by the end of the twentieth
century in Australia, measles had become a disease mostly
affecting young adults [1,2]. The first major measles out-
break in Australia involving predominantly young adults
occurred in Victoria between February and May 1999.
Approximately 85% of the 75 notified cases confirmed
with measles in this outbreak were born between 1968
and 1981 (aged between 18 and 31 years at the time) [2].
These young adults were most likely to be susceptible to
infection because of the timing of changes to measles vac-
cination practices in Australia. Measles vaccine was first
licensed in Australia in 1968, recommended for children
aged 15 months in 1971, and included for 12-month-old
infants in the first national childhood immunisation
schedule in 1975. Measles-mumps vaccine was intro-
duced in Victoria in February 1983 and measles-mumps-
rubella (MMR) was introduced in 1989 [3]. Prior to the
introduction of vaccine, most people acquired immunity
through infection with wild measles virus in childhood.
Despite suggestions of initially poor uptake [4], the avail-
ability of measles vaccine in Australia from 1968 lead to a
reduction in circulating wild measles virus, reflected in
decreased measles and measles encephalitis admissions to
Victoria's former infectious diseases hospital [5].
As a consequence of changes to vaccination policies, a
proportion of the 1968–82 birth cohort had not been
exposed to either wild or vaccine virus. Since 1999 mea-
sles outbreaks in Victoria have involved predominantly
young adults and unimmunised children. In three large
measles outbreaks in Victoria between 1999 and 2002, the
median age of cases has varied between 22 and 25 years
[2,6,7]. Estimates of susceptibility to measles in the 1968–
82 birth cohort ranged from 15–21% from two surveys
with sera collected in 1999, one using blood donors and
the other using residual diagnostic sera stored at the Vic-
torian Infectious Diseases Reference Laboratory [1]. Esti-
mated measles susceptibility at a national level was 9%
[8]. In recognition of residual measles susceptibility
among young adults, the Commonwealth Department of
Health funded an MMR immunisation program in the
financial year 2000–2001. The program targeted adults
aged 18–30 years [9]. Funding was provided to the states
for the purchase of vaccine for young adults who visited
their general practitioner in 2001–2. There were no spe-
cific funds for planning or advertising the campaign and
there was no provision, at the time, for any campaign eval-
uation. Some states ran programs that targeted tertiary stu-
dents [10] but young working adults were not directly
targeted.
This approach was very much in contrast to the national
measles control campaign, which had been conducted in
1998 targeting school-aged children. The campaign was
coordinated by the Commonwealth Department of
Health and had appropriate planning and resources to
provide school-based vaccinations. It resulted in an esti-
mated 94% measles immunity in children aged 6–11
years and 91% in children aged 12–18 years[11].
In order to provide an outcome evaluation of the young
adults measles campaign, the Commonwealth Depart-
ment of Health funded a national serosurvey in 2002, per-
formed by the National Centre for Immunisation
Research and Surveillance. An independent state-based
serosurvey was performed in Victoria. Our aim was to esti-
mate measles immunity in young Victorian adults follow-
ing the measles immunisation program and to compare
the results from the national and state serosurveys. Post
campaign serosurvey immunity estimates were compared
with previously published pre-campaign estimates [1,8].
We also reviewed all laboratory confirmed cases of mea-
sles in Victoria between 2000 and 2004.
Methods
Samples and sample size
Young adults targeted by the MMR campaign were aged
approximately 17–31 years in 1999, at the time of the first
large outbreak, and in the range 20–34 years in 2002. The
population aged 20–34 years in Victoria in 2002 was
1,056,474. We estimated measles immunity of Victorian
residents aged 20–34 years in 2002 (born 1968–82) one
year after the young adult immunisation program. For the
state-based evaluation, we used residual diagnostic sera
collected in 2002 and stored at the Victorian Infectious
Diseases Reference Laboratory. We compared the results
for the 2002 sample with previously published results for
1999 [1]. For the national evaluation, we compared the
sera submitted by Victorian diagnostic laboratories to two
national serosurveys in 1996–9 [8] and 2002 [12].
The estimated sample size for the 1999 state-based sero-
survey was 246, based on 80% immunity with 5% preci-
sion for a 95% confidence interval [1]. The 2002 state-
based serosurvey assumed age-specific immunity would
be unchanged and the sample size estimate was the same.
The sample size for the national serosurvey in 2002 was
calculated to detect a 5% difference in immunity in young
adults from the first serosurvey with 80% power and 95%
confidence [12]. National sample sizes were not intended
to be able to detect differences between states.
Assay protocol
Testing for the state-based surveys was performed at the
Victorian Infectious Diseases Reference Laboratory and
for the national surveys at the Institute for Clinical Pathol-
ogy and Medical Research in Sydney. Testing was done
using the Enzygnost (Dade Behring, Marburg, Germany)Page 2 of 6
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both laboratories. Using the alpha formula provided, the
manufacturer's instructions for the calculation of immu-
noglobulin class G (IgG) concentration based on optical
density (OD), were followed and immunity was deter-
mined as OD >= 0.2, equivalent to approximately 340
milli-International Units per millilitre (mIU/ml). Equivo-
cal samples were retested and reclassified as positive or
negative, where indicated. Final equivocal results were
counted as non-immune.
In the state-based serosurveys, serum samples that had
been submitted for measles or rubella testing were
excluded from all study samples and all serum samples
were anonymised. Ethics approval for the anonymous
testing of residual diagnostic sera has been obtained from
the Royal Melbourne Hospital Research Foundation
Human Ethics Committee. In the 2002 national serosur-
vey, sera excluded were those from patients known to be
immunocompromised, HIV positive, or those with a his-
tory of multiple transfusions in the three months prior to
sample collection. In the 1996–9 national serosurvey,
samples that had been tested for measles were also
excluded. Appropriate state and local ethics committees
approved the national serosurveys [11,12].
Analysis
Given the study design, there was no information availa-
ble about the vaccination history of individuals whose
sera were tested. We assumed measles vaccination policies
had affected measles immunity in the population and fur-
ther assumed that population age-specific immunity
would be reflected in the convenience samples. Analysis
of measles immunity was therefore based on the pre-
sumed effect of changes in measles immunisation policy
on the 1968–82 birth cohort. Samples from the state-
based study were analysed in two birth cohorts. For both
state-based serosurveys we analysed birth cohorts that
reflected changes made to immunisation policy affecting
infants aged 12 months in 1968–73 and 1974–82. Victo-
rian samples from the national serosurvey were analysed
as one birth cohort, 1968–82.
The state-based sample included equal numbers of each
age and the proportion positive by age group was calcu-
lated as all positive divided by all tested. Because a larger
number of sera were tested from younger ages in both
national samples, age group specific estimates of immu-
nity from the national sample were directly adjusted to
the age distribution of the Australian population in 2002.
Results for both serosurveys were imported into STATA
version 8 for analysis (StataCorp, College Station, Texas,
USA). Exact 95% confidence intervals for proportions
were calculated and Fisher's exact test was used to assess
the difference in proportions.
Laboratory confirmed measles in Victoria
An attempt is made to confirm all measles notifications in
Victoria by laboratory diagnosis at the Victorian Infectious
Diseases Reference Laboratory, the state, national and
WHO regional reference laboratory for measles. We
reviewed all laboratory confirmed measles cases on the
laboratory database between 2000 and 2004 and distin-
guished between clusters and sporadic cases, based on
epidemiological information gathered as part of
enhanced surveillance in Victoria [13] and genotyping of
cases [14,15].
Results
Immunity following the young adults MMR campaign, 
state-based serosurveys
Of all samples, 5.4% and 3.6% were equivocal in the 1999
and 2002 state-based serosurveys respectively and were
classified as not protected. Following the young adults
MMR campaign, there was a small non-significant
increase in overall immunity from 83.9% (95% CI, 79.4–
87.8) to 85.5% (95% CI, 80.8–89.4) between 1999 and
2002, but no evidence of any significant increase in the
proportion immune in either of the 1968–73 or the
1974–82 birth cohorts (Table 1). However the older birth
cohort (1968–73) was more likely to be immune in both
serosurveys, with differences in the proportion immune
of 8.6% (95% CI 0.7–16.5) and 9.3% (95% CI 1.5–17.1)
for the 1999 and 2002 serosurveys respectively.
Immunity following the young adults MMR campaign, 
national serosurveys
Ten Victorian laboratories contributed a range of 40–68
serum samples per laboratory to the 1996–9 serosurvey,
compared with seven laboratories contributing a range of
16–111 samples per laboratory to the 2002 serosurvey.
The Victorian Infectious Diseases Reference Laboratory
contributed a greater proportion of sera in the 2002 sero-
survey (34% in 2002 compared with 12% in 1999; Table
2). In each serosurvey, estimates of immunity from sera
stored at the Victorian Infectious Diseases Reference Lab-
oratory were lower than all except one other laboratory,
although no differences were statistically significant.
Excluding the Victorian Infectious Diseases Reference Lab-
oratory, four Victorian laboratories contributed reasona-
ble sample numbers in both surveys; three had lower
point estimates of immunity in the 2002 serosurvey and
one had a higher point estimate. Confining estimates of
immunity between surveys to these four laboratories and
the Victorian Infectious Diseases Reference Laboratory
resulted in an estimated decrease in immunity in the
1968–82 birth cohort from 90.4% to 81.9% (p < 0.001),
similar to the estimated decrease when all available data
were included (Table 2).Page 3 of 6
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After the large outbreak involving 75 cases in Victoria in
1999 [2], there were 16 outbreaks involving more than
one case in the state between 2000 and 2004. The maxi-
mum number of cases in any one outbreak was 22, while
20 cases were not associated with any further transmis-
sion. The median number of cases per outbreak, including
sporadic cases, was 1 and, for outbreaks involving more
than one case, was 2.5. The median age of all laboratory
confirmed cases in this period was 24.5 years.
Discussion
Estimates from the national and the state-based serosur-
veys of the proportion of young adults born between
1968–82, resident in Victoria and immune to measles in
2002, were in close agreement (84.2% and 85.5%, respec-
tively). Neither serosurvey provided evidence of increased
immunity in young adults following the targeted MMR
campaign. The important difference in the serosurveys
was the higher estimate of young adult immunity in Vic-
toria from the first national serosurvey. An apparent
decline in immunity among young Victorian adults in the
national serosurveys, evident in all except one of the Vic-
torian laboratories but not evident from the state-based
serosurveys, is not easy to explain on a population basis.
In the results of the national evaluation, other states did
not demonstrate a decrease in immunity among young
adults between serosurveys and immunity in Victoria in
1996–9 was similar to other states [12]. The higher esti-
mate of young adult immunity in the first national sero-
survey may be a sampling anomaly. We have no other
explanation for the finding. However we have previously
shown no significant population health difference in sus-
ceptibility to a number of vaccine preventable diseases
when comparing the 1996–9 national sample of residual
diagnostic sera from Victoria with sera obtained from a
three-stage random cluster survey in Victoria, suggesting
that residual diagnostic sera are representative of the pop-
ulation [16].
A decline in immunity in young Victorian adults, if it were
a valid finding, might suggest waning vaccine induced
immunity. Based on a small pilot study of 25 young
adults tested over a median period of approximately six
years, we found no evidence of waning immunity
between surveys. However we have no information on the
vaccination or exposure history of the individuals tested
and cannot draw any significant conclusions from this
observation. Given the low levels of circulating measles
virus in Victoria following interruption of endemic mea-
Table 2: National serosurvey estimates of measles immunity amongst young adults (born 1968–1982) in Victoria before (1996–9) and 
after (2002) the young adult measles immunisation program by laboratory
1996–9 serosurvey* 2002 serosurvey
Laboratory Samples 
tested
Percent of all samples 
tested (%)




Percent of all 
samples tested (%)
Percent measles protected 
by laboratory† (%)




VIDRL** 45 12.2 88.1 111 34.0 80.5 -7.65 0.2
Lab 2 68 18.4 90.4 46 14.1 80.6 -9.78 0.2
Lab 3 55 14.9 90.1 66 20.2 88.5 -1.62 0.6
Lab 4 40 10.8 86.7 16 4.9 96.9 10.16 0.3
Lab 5 43 11.6 95.7 38 11.7 83.3 -12.41 0.2
Other labs 118 32.0 91.2 5 1.5 80.0 -11.2 0.5
Total 369 100 91.0 282 100 84.2 -6.80 0.006
* 1996–8 serosurvey used for the 1968–80 birth cohort; 1999 serosurvey used for the 1981–2 birth cohort
† age-adjusted to the 2002 Australian population
** Victorian Infectious Diseases Reference Laboratory
Table 1: State-based estimates of measles immunity amongst young adults in Victoria before (1999) and after (2002) the young adult 
measles immunisation program
Measles vaccine Birth cohort Age 1999 (years) N Percent immune 
(95% CI)
Age 2002 (years) N Percent immune (95% CI) p-value 1999 vs 2002
Licensed 1968 1968–1973 26–31 120 89.2 (82.2–94.1) 29–34 112 91.1 (84.2–95.6) 0.79
Scheduled at age 12 months in 
1975, until 1983 when measles-
mumps vaccine was introduced
1974–1982 17–25 191 80.6 (74.3–86.0) 20–28 170 81.8 (75.1–87.3) 0.67
Total 1968–1982 17–31 311 83.9 (79.4–87.8) 20–34 282 85.5 (80.8–89.4) 0.65Page 4 of 6
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changes in antibody levels would reflect vaccination his-
tory. In a cohort study from Luxembourg of waning mea-
sles and rubella immunity with follow-up over 6.8 years,
it was suggested that, in the absence of booster vaccina-
tion, measles antibody decay following vaccination was
about 2.4% per year [17]. Several other studies have dem-
onstrated a decline in antibody titre over time following
vaccination but this has not been reported to occur in nat-
urally infected individuals [18-20].
Whether there has been a decline in immunity or not,
both studies conclude that residual susceptibility to mea-
sles among young Victorian adults remains around 15%
after the young adult MMR immunisation program. The
measles notification rate in Victoria has fluctuated since
the 2002 serosurvey and, although the rate was low in
2004 (0.3 per 100,000), the median age of notified cases
was 26 years [21]. The ongoing problem of residual sus-
ceptibility to measles among the young adult population,
first evident in Victoria from a number of outbreaks and
confirmed by serosurveys, has subsequently been demon-
strated by outbreaks affecting mainly young adults in
other Australian states [22-25].
The failure of the young adult measles campaign can be
attributed to the lack of central coordination; a very lim-
ited plan for targeting this age group through general prac-
tice visits; no budget for promoting the campaign; and a
fragmentation of strategies to engage and vaccinate the
target group in various states. In addition MMR doses dis-
tributed to the target population were not monitored and
vaccine coverage in the target population could not be
measured. A centrally coordinated and well-planned
young adult vaccination campaign, targeting both males
and females aged 15–39 years with a measles-rubella
(MR) vaccine, was successful in Costa Rica in May 2001.
MR coverage achieved in the campaign was 87% in the
30–34 year age group and greater than 90% in all other
target age groups [26]. The target population was
1,606,329, about 60% larger than the target population in
Victoria.
Conclusion
For reasons similar to those in Australia, young adults
remain susceptible to measles in other developed coun-
tries, such as the United States [27] and France [28]. While
it may be possible to maintain measles elimination in
these countries in the short term, residual susceptibility in
identified cohorts will need to be addressed to maintain
measles elimination and global eradication in the longer-
term [29].
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